Key result
Endothelial dysfunction plays a significant role in the onset and progression of cardiac allograft vasculopathy, highlighting the potential of endothelial protective drugs for prevention and therapy.
Targeting endothelial dysfunction with cardiovascular and immunosuppressive drugs may offer a therapeutic strategy for preventing and treating cardiac allograft vasculopathy in heart transplant recipients.
Answers are grounded in this paper and cite their sources.
Supports endothelial-targeted drug trials in heart transplant recipients; leaves open their efficacy for cardiac allograft vasculopathy prevention.
Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of this disease. Nitric oxide (NO) is the principal mediator of all endothelial protective effects, due to its antinflammatory, antiproliferative, immunomodulatory and vasorelaxant properties. CAV involves immunologic mechanisms operating in the context of common cardiovascular risk factors which lead to impaired endothelial function, mainly as a consequence of decreased NO bioavailability and excessive oxidative stress. Once dysfunctional, the endothelium promotes CAV lesion progression towards the diffuse narrowing of the coronary vasculature which characterizes advanced allograft vasculopathy. Recently, many studies showed the possibility to restore endothelial dysfunction with an associated potential improvement in clinical cardiovascular outcome. Therefore, growing interest deserves the possibility to exert an endothelial protective role shown by some currently used cardiovascular and immunosuppressive drugs, as well as the future development of new pharmacological compounds with selective endothelial protective properties as a target for successful prevention and therapy of CAV.
No takes yet. Share an insight, caveat, or question.
Osto et al. (2010) conducted a review in Cardiac allograft vasculopathy. Pharmacological interventions targeting endothelial dysfunction was evaluated. Endothelial dysfunction plays a significant role in the onset and progression of cardiac allograft vasculopathy, highlighting the potential of endothelial protective drugs for prevention and therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: